Marknaden stängd -
Andra börsplatser
|
5-dagars förändring | Förändring 1 jan. | ||
192,45 USD | −1,31 % |
|
+1,67 % | +8,30 % |
11.07. | AbbVie lanserar Refresh Advanced OMEGA-3 ögondroppar i Kanada | CI |
11.07. | Indiska Glenmark Pharma rusar 10% till rekordnivå efter licensavtal med AbbVie om cancerbehandling | RE |
Skatteperiod: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Lönsamhet | ||||||||||
Return on Assets | 8,19 | 8,22 | 10,06 | 8,07 | 8,49 | |||||
Return on Total Capital | 12,33 | 12,63 | 16,41 | 14,44 | 16,13 | |||||
Return On Equity % | 187,7 | 80,95 | 72,4 | 35,2 | 62,29 | |||||
Return on Common Equity | 185,81 | 80,52 | 72,14 | 34,91 | 61,94 | |||||
Marginalanalys | ||||||||||
Gross Profit Margin % | 69,31 | 69,19 | 71,53 | 69,21 | 70,37 | |||||
SG&A Margin | 21,54 | 21,13 | 20,82 | 23,76 | 23,41 | |||||
EBITDA Margin % | 48,4 | 49,91 | 54,13 | 48,53 | 47,43 | |||||
EBITA Margin % | 46,95 | 48,48 | 52,79 | 47,14 | 46,07 | |||||
EBIT Margin % | 34,27 | 34,75 | 39,54 | 32,51 | 32,54 | |||||
Income From Continuing Operations Margin % | 10,09 | 20,55 | 20,4 | 8,97 | 7,61 | |||||
Net Income Margin % | 10,08 | 20,54 | 20,39 | 8,95 | 7,59 | |||||
Net Avail. For Common Margin % | 9,95 | 20,41 | 20,29 | 8,87 | 7,52 | |||||
Normalized Net Income Margin | 18,35 | 19,06 | 22,49 | 18,41 | 18,21 | |||||
Levered Free Cash Flow Margin | 36,81 | 34,25 | 39,56 | 41,66 | 35,46 | |||||
Unlevered Free Cash Flow Margin | 40,16 | 36,95 | 41,96 | 44,22 | 38,58 | |||||
Tillgångsomslutning | ||||||||||
Asset Turnover | 0,38 | 0,38 | 0,41 | 0,4 | 0,42 | |||||
Fixed Assets Turnover | 9,69 | 9,35 | 10,06 | 9,53 | 9,72 | |||||
Receivables Turnover (Average Receivables) | 6,43 | 5,98 | 5,47 | 4,85 | 5,1 | |||||
Inventory Turnover (Average Inventory) | 5,49 | 5,38 | 4,93 | 4,36 | 4,03 | |||||
Kortfristig likviditet | ||||||||||
Current Ratio | 0,84 | 0,79 | 0,96 | 0,87 | 0,66 | |||||
Quick Ratio | 0,6 | 0,56 | 0,69 | 0,63 | 0,43 | |||||
Operating Cash Flow to Current Liabilities | 0,61 | 0,65 | 0,84 | 0,6 | 0,49 | |||||
Days Sales Outstanding (Average Receivables) | 56,93 | 61,05 | 66,74 | 75,29 | 71,71 | |||||
Days Outstanding Inventory (Average Inventory) | 66,69 | 67,86 | 74,06 | 83,78 | 90,79 | |||||
Average Days Payable Outstanding | 43,86 | 54,95 | 62,52 | 70,07 | 72,38 | |||||
Cash Conversion Cycle (Average Days) | 79,76 | 73,96 | 78,29 | 88,99 | 90,12 | |||||
Långsiktig solvens | ||||||||||
Total Debt/Equity | 665,01 | 502,7 | 373,59 | 582,66 | 2,02 tn | |||||
Total Debt / Total Capital | 86,93 | 83,41 | 78,88 | 85,35 | 95,29 | |||||
LT Debt/Equity | 598,66 | 420,56 | 348,61 | 511,9 | 1,81 tn | |||||
Long-Term Debt / Total Capital | 78,25 | 69,78 | 73,61 | 74,99 | 85,51 | |||||
Total Liabilities / Total Assets | 91,3 | 89,47 | 87,55 | 92,28 | 97,51 | |||||
EBIT / Interest Expense | 6,4 | 8,06 | 10,29 | 7,94 | 6,53 | |||||
EBITDA / Interest Expense | 9,16 | 11,72 | 14,24 | 11,99 | 9,64 | |||||
(EBITDA - Capex) / Interest Expense | 8,84 | 11,4 | 13,93 | 11,64 | 9,29 | |||||
Total Debt / EBITDA | 3,87 | 2,73 | 2,03 | 2,27 | 2,51 | |||||
Net Debt / EBITDA | 3,5 | 2,39 | 1,74 | 1,79 | 2,31 | |||||
Total Debt / (EBITDA - Capex) | 4,02 | 2,81 | 2,08 | 2,34 | 2,61 | |||||
Net Debt / (EBITDA - Capex) | 3,63 | 2,45 | 1,78 | 1,85 | 2,39 | |||||
Tillväxt jämfört med föregående år | ||||||||||
Total Revenues, 1 Yr. Growth % | 37,69 | 22,69 | 3,3 | −6,44 | 3,71 | |||||
Gross Profit, 1 Yr. Growth % | 22,92 | 22,48 | 3,6 | −9,48 | 5,46 | |||||
EBITDA, 1 Yr. Growth % | 41,08 | 26,52 | 6,84 | −16,12 | 1,37 | |||||
EBITA, 1 Yr. Growth % | 41,01 | 26,71 | 7,12 | −16,45 | 1,36 | |||||
EBIT, 1 Yr. Growth % | 14,62 | 24,4 | 9,89 | −23,07 | 3,81 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | −41,36 | 149,87 | 2,56 | −58,86 | −12,05 | |||||
Net Income, 1 Yr. Growth % | −41,44 | 150,04 | 2,55 | −58,91 | −12,03 | |||||
Normalized Net Income, 1 Yr. Growth % | 10,67 | 27,41 | 12,93 | −23,4 | 2,53 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | −48,48 | 137,13 | 2,79 | −58,97 | −12,13 | |||||
Accounts Receivable, 1 Yr. Growth % | 62,53 | 13,09 | 12,8 | −0,88 | −2,12 | |||||
Inventory, 1 Yr. Growth % | 82,57 | −5,5 | 14,42 | 14,53 | 2 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 85,81 | −4,41 | −3,41 | 1,08 | 2,16 | |||||
Total Assets, 1 Yr. Growth % | 68,96 | −2,68 | −5,27 | −2,95 | 0,33 | |||||
Tangible Book Value, 1 Yr. Growth % | 142,6 | −9,72 | −11,39 | −5,83 | 18,26 | |||||
Common Equity, 1 Yr. Growth % | −260,01 | 17,83 | 11,98 | −39,96 | −67,91 | |||||
Cash From Operations, 1 Yr. Growth % | 32 | 29,5 | 9,51 | −8,44 | −17,66 | |||||
Capital Expenditures, 1 Yr. Growth % | 44,57 | −1,38 | −11,69 | 11,8 | 25,35 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 100,26 | 14,17 | 14,25 | −1,47 | −11,72 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 92,93 | 12,88 | 12,7 | −1,4 | −9,52 | |||||
Dividend Per Share, 1 Yr. Growth % | 10,25 | 9,71 | 7,53 | 4,9 | 5,01 | |||||
Sammansatt Årlig Tillväxthastighet Över Två År | ||||||||||
Total Revenues, 2 Yr. CAGR % | 18,26 | 29,97 | 12,58 | −1,69 | −1,49 | |||||
Gross Profit, 2 Yr. CAGR % | 12,61 | 22,7 | 16,6 | −1,67 | −2,29 | |||||
EBITDA, 2 Yr. CAGR % | 27,27 | 31,33 | 21,9 | −3,46 | −3,51 | |||||
EBITA, 2 Yr. CAGR % | 27,55 | 31,32 | 22,32 | −3,46 | −3,58 | |||||
EBIT, 2 Yr. CAGR % | 14,75 | 17,08 | 25,07 | −5,46 | −4,8 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | −9,85 | 21,05 | 60,09 | −35,04 | −39,85 | |||||
Net Income, 2 Yr. CAGR % | −9,91 | 21,01 | 60,13 | −35,09 | −39,88 | |||||
Normalized Net Income, 2 Yr. CAGR % | 12,17 | 16,14 | 29,65 | −4,01 | −4,95 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | −13,79 | 10,53 | 56,12 | −35,06 | −39,96 | |||||
Accounts Receivable, 2 Yr. CAGR % | 28,01 | 35,58 | 12,95 | 5,74 | −1,5 | |||||
Inventory, 2 Yr. CAGR % | 43,61 | 31,35 | 3,98 | 14,47 | 8,08 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 45,97 | 33,27 | −3,91 | −1,19 | 1,62 | |||||
Total Assets, 2 Yr. CAGR % | 59,27 | 28,23 | −3,98 | −4,12 | −1,32 | |||||
Tangible Book Value, 2 Yr. CAGR % | 50,66 | 48 | −10,56 | −8,65 | 5,53 | |||||
Common Equity, 2 Yr. CAGR % | 24,43 | 37,31 | 14,87 | −18 | −56,1 | |||||
Cash From Operations, 2 Yr. CAGR % | 14,45 | 30,75 | 19,09 | 0,14 | −13,17 | |||||
Capital Expenditures, 2 Yr. CAGR % | 11,84 | 19,4 | −6,68 | −0,64 | 18,38 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 16,55 | 48,21 | 18,98 | 8,02 | −3,06 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 17,8 | 44,98 | 17,13 | 7,18 | −2,06 | |||||
Dividend Per Share, 2 Yr. CAGR % | 10,69 | 9,98 | 8,62 | 6,21 | 4,96 | |||||
Treårig Sammansatt Årlig Tillväxthastighet | ||||||||||
Total Revenues, 3 Yr. CAGR % | 17,53 | 19,72 | 20,4 | 5,85 | 0,08 | |||||
Gross Profit, 3 Yr. CAGR % | 13,82 | 15,81 | 17,15 | 7,16 | 0,65 | |||||
EBITDA, 3 Yr. CAGR % | 23,48 | 27,02 | 24,55 | 7,62 | −1,88 | |||||
EBITA, 3 Yr. CAGR % | 23,74 | 27,27 | 24,71 | 7,73 | −1,88 | |||||
EBIT, 3 Yr. CAGR % | 15,18 | 17,88 | 17,24 | 6,36 | −2,47 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | −4,51 | 26,64 | 14,54 | 1,78 | −28,14 | |||||
Net Income, 3 Yr. CAGR % | −4,56 | 26,61 | 14,51 | 1,75 | −28,17 | |||||
Normalized Net Income, 3 Yr. CAGR % | 14,57 | 17,03 | 18,03 | 8,79 | −1,87 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | −6,24 | 20,79 | 7,88 | 0 | −28,17 | |||||
Accounts Receivable, 3 Yr. CAGR % | 20,14 | 22,83 | 27,51 | 8,14 | 3,05 | |||||
Inventory, 3 Yr. CAGR % | 27,29 | 24,91 | 25,45 | 7,39 | 10,16 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 29,89 | 26,76 | 19,71 | −2,28 | −0,09 | |||||
Total Assets, 3 Yr. CAGR % | 28,61 | 35,15 | 15,92 | −3,64 | −2,66 | |||||
Tangible Book Value, 3 Yr. CAGR % | 39,09 | 27,02 | 24,74 | −9,01 | −0,44 | |||||
Common Equity, 3 Yr. CAGR % | 36,89 | 22,19 | 28,29 | −7,47 | −40,02 | |||||
Cash From Operations, 3 Yr. CAGR % | 20,87 | 19,26 | 23,25 | 9,1 | −6,19 | |||||
Capital Expenditures, 3 Yr. CAGR % | 14,69 | 7,25 | 7,98 | −0,88 | 7,36 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 39,46 | 15,75 | 37,87 | 11,73 | 0,99 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 38,43 | 16,14 | 35,1 | 10,59 | 1,3 | |||||
Dividend Per Share, 3 Yr. CAGR % | 22,55 | 10,37 | 9,16 | 7,36 | 5,81 | |||||
Sammansatt Årlig Tillväxthastighet Över Fem År | ||||||||||
Total Revenues, 5 Yr. CAGR % | 14,91 | 16,99 | 15,52 | 10,65 | 11,11 | |||||
Gross Profit, 5 Yr. CAGR % | 11,26 | 14,4 | 14,04 | 8,47 | 8,95 | |||||
EBITDA, 5 Yr. CAGR % | 18 | 21,01 | 21,69 | 14 | 10,44 | |||||
EBITA, 5 Yr. CAGR % | 18,32 | 21,27 | 21,98 | 14,14 | 10,44 | |||||
EBIT, 5 Yr. CAGR % | 12,13 | 15,21 | 17,45 | 8,17 | 5,17 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | −2,12 | 14,17 | 17,41 | −3,04 | −11,47 | |||||
Net Income, 5 Yr. CAGR % | −2,14 | 14,16 | 17,39 | −3,08 | −11,5 | |||||
Normalized Net Income, 5 Yr. CAGR % | 10,95 | 15,46 | 18,49 | 8,4 | 5,25 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | −2,77 | 12,18 | 14,97 | −5,76 | −14,66 | |||||
Accounts Receivable, 5 Yr. CAGR % | 13,28 | 15,96 | 17,21 | 15,68 | 15 | |||||
Inventory, 5 Yr. CAGR % | 14 | 16,72 | 17,4 | 20,63 | 18,19 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 19,09 | 17,66 | 15,14 | 14,74 | 12,12 | |||||
Total Assets, 5 Yr. CAGR % | 23,2 | 17,26 | 14,42 | 17,81 | 8,69 | |||||
Tangible Book Value, 5 Yr. CAGR % | 28,89 | 18,55 | 16,57 | 11,33 | 16,67 | |||||
Common Equity, 5 Yr. CAGR % | 27,08 | 27,15 | 27,62 | 4,17 | −16,46 | |||||
Cash From Operations, 5 Yr. CAGR % | 18,48 | 26,47 | 20,15 | 11,21 | 7,14 | |||||
Capital Expenditures, 5 Yr. CAGR % | 8,45 | 10,44 | 5,61 | 4,02 | 12,03 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 19,29 | 28,36 | 29,87 | 12,76 | 17,92 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 19,88 | 27,43 | 28,57 | 12,62 | 17,08 | |||||
Dividend Per Share, 5 Yr. CAGR % | 18,17 | 17,71 | 16,77 | 8,68 | 7,46 |
- Börsen
- Aktier
- ABBV Aktie
- Finanser AbbVie Inc.
- Finansiella nyckeltal
Välj din utgåva
All finansiell information anpassad till den nationella nivån

MarketScreener is also available in this country: United States.
Switch edition